Articles
Page 4 of 28
-
Citation: Alzheimer's Research & Therapy 2022 14:82
-
Correction: Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)—study protocol for a randomized controlled trial
Citation: Alzheimer's Research & Therapy 2022 14:81 -
Longitudinal evaluation of neuroinflammation and oxidative stress in a mouse model of Alzheimer disease using positron emission tomography
Validation of new biomarkers of Alzheimer disease (AD) is crucial for the successful development and implementation of treatment strategies. Additional to traditional AT(N) biomarkers, neuroinflammation biomar...
Citation: Alzheimer's Research & Therapy 2022 14:80 -
The relationship between retinal layers and brain areas in asymptomatic first-degree relatives of sporadic forms of Alzheimer’s disease: an exploratory analysis
Two main genetic risks for sporadic Alzheimer’s disease (AD) are a family history and ɛ4 allele of apolipoprotein E. The brain and retina are part of the central nervous system and share pathophysiological mec...
Citation: Alzheimer's Research & Therapy 2022 14:79 -
Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease
Synaptic dysfunction and degeneration are central to Alzheimer’s disease (AD) and have been found to correlate strongly with cognitive decline. Thus, studying cerebrospinal fluid (CSF) biomarkers reflecting sy...
Citation: Alzheimer's Research & Therapy 2022 14:78 -
Mapping the genetic landscape of early-onset Alzheimer’s disease in a cohort of 36 families
Many families with clinical early-onset Alzheimer’s disease (EOAD) remain genetically unexplained. A combination of genetic factors is not standardly investigated. In addition to monogenic causes, we evaluated...
Citation: Alzheimer's Research & Therapy 2022 14:77 -
Retraction Note: Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer’s disease pathogenesis
This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13195-017-0280-8.
Citation: Alzheimer's Research & Therapy 2022 14:76 -
Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies
No population-based cohort study investigated a potential inverse association between long-term low-dose acetylsalicylic acid (ASA) use and all-cause dementia and its two most common sub-types Alzheimer’s dise...
Citation: Alzheimer's Research & Therapy 2022 14:75 -
Association between Life’s Simple 7 and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology in cognitively intact adults: the CABLE study
This study sought to explore the association between Life’s Simple 7 (LS7) and cerebrospinal fluid (CSF) Alzheimer’s disease (AD) pathological biomarkers in the cognitively normal northern Chinese population.
Citation: Alzheimer's Research & Therapy 2022 14:74 -
The role of basket trials in drug development for neurodegenerative disorders
Drug development for neurodegenerative disorders (NDDs) is a long, complex, and expensive enterprise. Methods to optimize drug development for NDDs are needed. Basket trials have been widely used in oncology a...
Citation: Alzheimer's Research & Therapy 2022 14:73 -
Dynamic functional connectivity patterns associated with dementia risk
This study assesses the relationships between dynamic functional network connectivity (DFNC) and dementia risk.
Citation: Alzheimer's Research & Therapy 2022 14:72 -
Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study
Synaptic dysfunction is an early core feature of Alzheimer’s disease (AD), closely associated with cognitive symptoms. Neuregulin 1 (NRG1) is a growth and differentiation factor with a key role in the developm...
Citation: Alzheimer's Research & Therapy 2022 14:71 -
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Citation: Alzheimer's Research & Therapy 2022 14:70 -
ADataViewer: exploring semantically harmonized Alzheimer’s disease cohort datasets
Currently, Alzheimer’s disease (AD) cohort datasets are difficult to find and lack across-cohort interoperability, and the actual content of publicly available datasets often only becomes clear to third-party ...
Citation: Alzheimer's Research & Therapy 2022 14:69 -
Explaining the association between social and lifestyle factors and cognitive functions: a pathway analysis in the Memento cohort
This work aimed to investigate the potential pathways involved in the association between social and lifestyle factors, biomarkers of Alzheimer’s disease and related dementia (ADRD), and cognition.
Citation: Alzheimer's Research & Therapy 2022 14:68 -
Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
Recent advances in disease-modifying treatments highlight the need for accurately identifying individuals in early Alzheimer’s disease (AD) stages and for monitoring of treatment effects. Plasma measurements o...
Citation: Alzheimer's Research & Therapy 2022 14:67 -
β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer’s disease and predicts cerebral amyloidosis
Blood biomarkers that can be used for preclinical Alzheimer’s disease (AD) diagnosis would enable trial enrollment at a time when the disease is potentially reversible. Here, we investigated plasma neuronal-de...
Citation: Alzheimer's Research & Therapy 2022 14:66 -
Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
Blood phosphorylated tau (p-tau) forms are promising Alzheimer’s disease (AD) biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) plasma is limited. Firstly, we assessed th...
Citation: Alzheimer's Research & Therapy 2022 14:65 -
The course of primary progressive aphasia diagnosis: a cross-sectional study
The primary progressive aphasia (PPA) diagnosis trajectory is debated, as several changes in diagnosis occur during PPA course, due to phenotype evolution from isolated language alterations to global cognitive...
Citation: Alzheimer's Research & Therapy 2022 14:64 -
Subclinical carotid artery atherosclerosis and cognitive function in older adults
The combined effects of increased life expectancy and the considerable number of persons reaching old age will magnify the dementia epidemic in the USA. Demonstration that subclinical atherosclerosis precedes ...
Citation: Alzheimer's Research & Therapy 2022 14:63 -
Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes
The entry of artificial intelligence into medicine is pending. Several methods have been used for the predictions of structured neuroimaging data, yet nobody compared them in this context.
Citation: Alzheimer's Research & Therapy 2022 14:62 -
Cerebrospinal fluid lactate levels along the Alzheimer’s disease continuum and associations with blood-brain barrier integrity, age, cognition, and biomarkers
Cerebrospinal fluid (CSF) lactate levels have been suggested to be associated with disease severity and progression in several neurological diseases as an indicator of impaired energy metabolism, neuronal deat...
Citation: Alzheimer's Research & Therapy 2022 14:61 -
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort
Cerebrospinal fluid (CSF) analysis for detecting amyloid positivity may be as reliable as positron emission tomography (PET). We evaluated the performance of the amyloid beta (Aβ)42/40 ratio for predicting amy...
Citation: Alzheimer's Research & Therapy 2022 14:60 -
Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice
Slowed clearance of amyloid β (Aβ) is believed to underlie the development of Aβ plaques that characterize Alzheimer’s disease (AD). Aβ is cleared in part by the glymphatic system, a brain-wide network of peri...
Citation: Alzheimer's Research & Therapy 2022 14:59 -
Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease
There is currently a lack of reliable and easily accessible biomarkers predicting cognitive decline in Alzheimer’s disease (AD). Synaptic dysfunction and loss occur early in AD and synaptic loss measured in th...
Citation: Alzheimer's Research & Therapy 2022 14:58 -
The retinal ganglion cell layer reflects neurodegenerative changes in cognitively unimpaired individuals
To evaluate a wide range of optical coherence tomography (OCT) parameters for possible application as a screening tool for cognitively healthy individuals at risk of Alzheimer’s disease (AD), assessing the pot...
Citation: Alzheimer's Research & Therapy 2022 14:57 -
Glucose metabolism and AD: evidence for a potential diabetes type 3
Alzheimer’s disease is the most prevalent cause of dementia in the elderly. Neuronal death and synaptic dysfunctions are considered the main hallmarks of this disease. The latter could be directly associated t...
Citation: Alzheimer's Research & Therapy 2022 14:56 -
Comparison and aggregation of event sequences across ten cohorts to describe the consensus biomarker evolution in Alzheimer’s disease
Previous models of Alzheimer’s disease (AD) progression were primarily hypothetical or based on data originating from single cohort studies. However, cohort datasets are subject to specific inclusion and exclu...
Citation: Alzheimer's Research & Therapy 2022 14:55 -
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
The need for preventive therapies that interrupt the progression of Alzheimer’s disease (AD) before the onset of symptoms or when symptoms are emerging is urgent and has spurred the ongoing development of dise...
Citation: Alzheimer's Research & Therapy 2022 14:54 -
Chemical genetic activation of the cholinergic basal forebrain hippocampal circuit rescues memory loss in Alzheimer’s disease
The degeneration of the cholinergic circuit from the basal forebrain to the hippocampus contributes to memory loss in patients suffering from Alzheimer’s disease (AD). However, the internal relationships betwe...
Citation: Alzheimer's Research & Therapy 2022 14:53 -
Reconfigured metabolism brain network in asymptomatic microtubule-associated protein tau mutation carriers: a graph theoretical analysis
Studies exploring topological properties of the metabolic network during the presymptomatic stage of genetic frontotemporal dementia (FTD) are scarce. However, such knowledge is important for understanding bra...
Citation: Alzheimer's Research & Therapy 2022 14:52 -
Mesial temporal tau in amyloid-β-negative cognitively normal older persons
Tau deposition in the mesial temporal lobe (MTL) in the absence of amyloid-β (Aβ−) occurs with aging. The tau PET tracer 18F-MK6240 has low non-specific background binding so is well suited to exploration of earl...
Citation: Alzheimer's Research & Therapy 2022 14:51 -
Emotional prosody recognition is impaired in Alzheimer’s disease
The ability to understand emotions is often disturbed in patients with cognitive impairments. Right temporal lobe structures play a crucial role in emotional processing, especially the amygdala, temporal pole ...
Citation: Alzheimer's Research & Therapy 2022 14:50 -
What’s the cut-point?: a systematic investigation of tau PET thresholding methods
Tau positron emission tomography (PET) is increasing in popularity for biomarker characterization of Alzheimer’s disease (AD), and recent frameworks rely on tau PET cut-points to stage individuals along the AD...
Citation: Alzheimer's Research & Therapy 2022 14:49 -
Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis
Neuropsychiatric symptoms (NPS) are common in individuals with Alzheimer’s disease (AD) dementia, but substantial heterogeneity exists in the manifestation of NPS. Sex differences may explain this clinical var...
Citation: Alzheimer's Research & Therapy 2022 14:48 -
APOE ε4, Alzheimer’s disease neuropathology and sleep disturbance, in individuals with and without dementia
Apolipoprotein E epsilon 4 (APOE-ε4) carrier status is an established risk factor for Alzheimer’s disease (AD) dementia. It has also been linked with sleep disturbance in healthy older adults and increased insomn...
Citation: Alzheimer's Research & Therapy 2022 14:47 -
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
Up to now, there are no clinically available minimally invasive biomarkers to accurately identify mild cognitive impairment (MCI) patients who are at greater risk to progress to Alzheimer’s disease (AD) dement...
Citation: Alzheimer's Research & Therapy 2022 14:46 -
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease
The three core pathologies of Alzheimer’s disease (AD) are amyloid pathology, tau pathology, and neurodegeneration. Biomarkers exist for each. Neurodegeneration is often detected by neuroimaging, and we hypoth...
Citation: Alzheimer's Research & Therapy 2022 14:45 -
Correction to: Psychotherapeutic interventions in individuals at risk for Alzheimer’s dementia: a systematic review
Citation: Alzheimer's Research & Therapy 2022 14:44 -
Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort
FACEmemory® is the first computerized, self-administered verbal episodic memory test with voice recognition. It can be conducted under minimal supervision and contains an automatic scoring system to avoid admi...
Citation: Alzheimer's Research & Therapy 2022 14:43 -
Correction to: Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s amyloidosis
Citation: Alzheimer's Research & Therapy 2022 14:42 -
A multi-regression framework to improve diagnostic ability of optical coherence tomography retinal biomarkers to discriminate mild cognitive impairment and Alzheimer’s disease
Diagnostic performance of optical coherence tomography (OCT) to detect Alzheimer’s disease (AD) and mild cognitive impairment (MCI) remains limited. We assessed whether compensating the circumpapillary retinal...
Citation: Alzheimer's Research & Therapy 2022 14:41 -
Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer’s disease with an implantable ultrasound device
Temporary disruption of the blood-brain barrier (BBB) using pulsed ultrasound leads to the clearance of both amyloid and tau from the brain, increased neurogenesis, and mitigation of cognitive decline in pre-c...
Citation: Alzheimer's Research & Therapy 2022 14:40 -
Novel diagnostic tools for identifying cognitive impairment using olfactory-stimulated functional near-infrared spectroscopy: patient-level, single-group, diagnostic trial
Basic studies suggest that olfactory dysfunction and functional near-infrared spectroscopy (fNIRS) can be used as tools for the diagnosis of mild cognitive impairment (MCI); however, real-world evidence is lac...
Citation: Alzheimer's Research & Therapy 2022 14:39 -
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Analysis of functional brain networks in Alzheimer’s disease (AD) has been hampered by a lack of reproducible, yet valid metrics of functional connectivity (FC). This study aimed to assess both the sensitivity...
Citation: Alzheimer's Research & Therapy 2022 14:38 -
Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer’s disease: a potential early sign of AD
Thioredoxin-80 (Trx80) is a cleavage product from the redox-active protein Thioredoxin-1 and has been previously described as a pro-inflammatory cytokine secreted by immune cells. Previous studies in our group...
Citation: Alzheimer's Research & Therapy 2022 14:37 -
Relationship of sex differences in cortical thickness and memory among cognitively healthy subjects and individuals with mild cognitive impairment and Alzheimer disease
An aging society has increased rates of late onset Alzheimer disease dementia (ADD), the most common form of age-related dementia. This neurodegenerative disease disproportionately affects women.
Citation: Alzheimer's Research & Therapy 2022 14:36 -
Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer’s disease: a cross-sectional analysis from the SILCODE study
Plasma amyloid-β (Aβ) may facilitate identification of individuals with brain amyloidosis. Gut microbial dysbiosis in Alzheimer’s disease (AD) is increasingly being recognized. However, knowledge about alterat...
Citation: Alzheimer's Research & Therapy 2022 14:35 -
Economic and caregiver impact of Alzheimer’s disease across the disease spectrum: a cohort study
Alzheimer’s disease (AD) substantially increases health-related costs. This study investigates direct medical costs and characterizes the caregiver burden across AD stages.
Citation: Alzheimer's Research & Therapy 2022 14:34 -
Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage
Positron emission tomography (PET) with amyloid tracers (amy-PET) allows the quantification of pathological amyloid deposition in the brain tissues, including the white matter (WM). Here, we evaluate amy-PET u...
Citation: Alzheimer's Research & Therapy 2022 14:33
Follow
- ISSN: 1758-9193 (electronic)